Bone Restoration in Diabetic Osteolysis and Therapeutic Targets

Thenmozhi A1*, Nagalakshmi K2, Shila S1 and Rasappan P3

1Research and Development Centre, Bharathiar University, Coimbatore, India
2Department of Biochemistry, DG Vaishnav College, Chennai, India
3VRR Institute of Biomedical Science, Kattupakkam, Chennai, India

Abstract

Bone, being a key structural support of the body, undergoes dynamic micro structural remodelling all over life to control automatic stress and calcium requirement. Neurovascular, visual, renal complications added with osteopenia and osteoporosis are main unbearable problems in diabetes mellitus (DM). It is clear that hyperglycaemia in diabetes mellitus leads to glucose toxicity which directly suppresses adipogenic delineation of the osteoblast precursors which depreciate bone feature and strength which augment propensity to fracture. A number of risk factors including oxidative stress, apoptosis and abnormal intracellularCa2+ metabolism have been postulated to play a function in the inception and progress of osteoporosis in diabetes. This review determines to discuss the most recent findings of mechanisms concerned in the progression of osteoporosis in diabetes. We emphasize the role of signalling molecules in osteoclastogenesis as therapeutic targets in the prevention and treatment of diabetic osteolysis. Increasing validation during the last decade suggests that zinc as nutraceutical suppresses calcium/calcineurin pathway and many compounds are potent inhibitors of osteoclast synthesis by blocking RANKL pathway, an emerging concept that is gaining acceptance. The characteristic of impediment and management of DM-induced osteolysis should be an effective glycaemic control. Hence, we propose to accentuate that Zinc combined with suitable anti-diabetic drugs and inhibitors of osteoclastogenesis may represent a potential therapeutic target in Diabetes mellitus for the prevention, reduction of fracture risk and treatment of osteolysis by suppressing osteoclastogenesis via calcium, calcineurin and RANKL pathway.

Keywords: Diabetes; Osteoclast; NF-k B; TRAP; Calcineurin

Introduction

Diabetes is a collection of metabolic diseases which arises due to defective insulin secretion, insulin resistance, or both and categorized by hyperglycaemia. The chronic hyperglycaemia of diabetes is related with long-term damage, dysfunction, and breakdown of different organs, particularly the eyes, kidneys, nerves, heart, and blood vessels [1]. International Diabetes Federation has estimated the number of diabetic subjects worldwide in 2015 was 415 million and with the present growth rate it is expected rise up to 642 million in 2040 [2]. Metabolic bone diseases, osteoporosis and low-impact fractures have been related with Diabetes. Frequent fall in geriatric subjects has also been reported [3,4]. Bone is an extremely active tissue that is subjected to constant remodeling, which is regulated by diverse factors, including cytokines/chemokines, hormones, and mechanical stimuli [5,6]. Bone homeostasis is regulated by Linking bone development by osteoblasts and bone resorption by osteoclasts [7]. Osteopenic disorders such as osteoporosis, rheumatoid arthritis, Paget’s disease, and lytic bone metastases of malignancies occur due to imbalance in bone resorption by osteoclasts compared to bone construction by osteoblasts [6]. Most drugs used in the healing of osteoporosis are anti-resorptive in action. At present the key pharmacological approaches for management of bone loss are bisphosphonates, oestrogen, and calcitonin. However, there are variable side effects from the long-term use of these drugs such as constipation, diarrhoea, tumorigenic, cardiovascular effects, and osteonecrosis of the jaw [8,9].

Literature Review

Tartrate-resistant acid phosphatase (TRAP)-positive multinucleated cells are produced from Osteoclast precursor cells of monocyte-macrophage lineage. The actin cytoskeleton is streamlined multinucleated cells are produced from Osteoclast precursor cells of...
activation of the pro-inflammatory transcription factor, nuclear factor-kappa B (NF-κ B), by protein kinase C in vitro [21]. The non-enzymatic reaction of glucose and increased fatty acid oxidation forms advanced glycation end products (AGEs). Intracellular hyperglycaemia is the principal initiating condition in the development of both intracellular and extracellular AGEs [22]. AGE binding to AGE receptors can induce the formation of reactive oxygen species, the activation of NF-κ B and the production of inflammatory cytokines such as tumour necrosis factor-alpha (TNF-α) [23]. Oxidative stress is fundamental to the progress of insulin resistance and diabetic complications [24,25]. Oxidative stress plays a significant part in diabetic complications. Hyperglycaemia leads to the over production of super oxides in mitochondria. NF-κ B, p38, MAPK and the JNK/SAPK pathway are susceptible to oxidative stress, which is connected to impaired insulin action and the development of the late diabetic complications [26]. As a result of cross-talk between adipose cells, macrophages, and other immune cells that infiltrate the expanding adipose tissue, a most important site, inflammatory mediators are produced [26]. Pro-inflammatory factors, such as tumour necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6 and IL-18, are augmented in diabetes mellitus which contribute to insulin resistance by both JNK and the inhibitor of nuclear factor kappa-B kinase (IKKβ)/NF-κ B pathway [27]. Enhanced formation of inflammatory cytokines contributes to insulin resistance and the damage of beta cells in the pancreas and is a major aspect in the progress of diabetic complications [28,29].

Impact of Diabetes on Bone and Osteoclasts

Clinical evidence indicates that bone quality is affected in patients with type 2 diabetes mellitus despite of normal or even high bone mineral density [30]. Dana et al. [30,31] have observed a considerably higher number of multi-nucleated and giant murine osteoclasts in db/db-derived cultures compared to C57BL/6 controls and also determined that analogous phenomenon occurred in human disease. Osteoclasts were derived from peripheral blood monocytes of individuals with and without T2DM. As an indicative of increased osteoclast activity human subjects with T2DM display increased circulating levels of tartrate-resistant acid phosphatase in serum due to the diabetic polyol pathway [29,32,33]. Anxiety is the cause of prolonged inflammation in diabetes, which may lead to enhanced osteoclastogenesis. Diabetes increases osteoclast development in various conditions like periodontal disease, fracture healing and osteoporosis (Figure 1).

Accelerated bone loss, osteopenia and osteoporosis are in Diabetes mellitus (DM) due to increased osteoclast role and decreased osteoblast function. Macrophage colony stimulating factor (M-CSF), tumour necrosis factor (TNF-α) and receptor activator of nuclear factor-k B ligand (RANKL) are all Osteoblast-derived activators of osteoclast production and segregation where by Hyperglycaemia induces manufacture of these factors. Hyperglycaemia decreases runt related transcription factor (Runx)-2, osteocalcin and osteopontin expressions as a consequence suppression of osteoblast proliferation and function occurs. As indicated by the overexpression of adipocyte differentiation markers, Adipogenic differentiation of mesenchymal stem cells is increased including peroxisome proliferator-activated receptor (PPAR) adipocyte fatty acid binding protein (AP), adipin and resistin [34].

Poor glycaemic control leads to increased bone resorption and bone loss in subjects with T1DM or T2DM [35]. The higher levels of IL-1β, TNF-α and prostaglandin E2 in Diabetic animals with periodontitis induce and extend osteoclast mediated resorption [36]. Individuals with T1DM have increased levels of IL-17 and IL-23, which promote osteoclast formation through RANKL. Diabetic rats with periodontitis and T1DM have a 2 to 4-fold increase in the number of osteoclasts [37,38]. Compared to infected normoglycaemic control T2DM rats have a 2 to 4-fold rise in osteoclasts induced by periodontal infection [39]. Correspondingly, human subjects with T2DM and periodontitis have significantly increased levels of TNF-α, IL-1β and IL-6 connected with delayed inflammation and increased lipid peroxidation and dyslipidaemia [38,40,41]. Increased RANKL/OPG ratios and TNF-α levels that contribute to greater bone resorption are observed in diabetes. In human subjects, the ratio of RANKL/OPG and TNF-α levels are increased in inadequately controlled diabetics [42]. In diabetic’s fatty

---

**Figure 1:** Effects of diabetes mellitus on bone metabolism and bone quality.
acid levels may also add to augmented osteoclastogenesis. Cathepsin K expression is elevated compared to control group, in streptozotocin-induced T1DM rats, representing increased osteoclast activity [43]. In T2DM rats, osteoclastic bone resorption is enhanced compared to normo glycaemic controls [44]. In diabetic mice, macrophage-colony stimulating factor, vascular endothelial growth factor-A, TNF-α and receptor activator of nuclear factor kappa-B ligand (RANKL) are up regulated which can directly proceed osteoclast segregation and activation [45,46]. Mitochondrial ROS levels are elevated, in subjects with T2DM, which promote RANKL-mediated osteoclast differentiation and function [47]. Increased fatty acid levels in patients with diabetes mellitus can induce osteoclastogenesis by enhancing TNF-α [48]. Enhanced osteoclast development in reaction to M-CSF and RANKL was exhibited by T2DM mice [32]. AGEs might also enhance osteoclast activity [31,49,50] support the concept that AGEs contribute to osteoclast formation in subjects with diabetes and mice that lack the receptor for AGE, RAGE displayed increased bone mass and decreased osteoclast numbers compared to wild-type mice [49].

**Impact of Diabetes on Osseointegration- is a Contraindication in Orthopaedic Prosthesis**

The reaction of parathyroid hormone that regulates the metabolism of phosphorus and calcium is altered by hyperglycaemia which inhibits osteoblast differentiation.

**In vitro** studies by He et al. support that chronic hyperglycaemia is a stimulus for bone resorption which affects different tissue structures and produces an inflammatory effect. In addition, it produces a harmful consequence on the bone matrix and its system and also affects adherence, growth and amassing of extra-cellular matrix [50]. Mineral homeostasis and production of osteoid has been shown to be evidently diminished in diverse experimental models of diabetes [51]. Diabetes is at present a virtual contraindication for implant management. The investigation of the effect of diabetes on implants has exposed an alteration in bone remodelling processes and deficient mineralization, leading to less bone absorption. The amount of bone formed is analogous when comparing diabetes-induced animals with controls but there is a decline in the bone-implant contact in diabetics [52,53]. The decrease in the levels of bone-implant success in diabetics confirms that diabetes reduces bone integration. This situation may be reversed by treating the Failure of orthopaedic hyperglycaemia and maintaining near-normal glucose levels [54]. There is an advanced risk of implant failure in diabetic patients; Ana Mellado et al. have shown that the optimization of glycaemic control improves the degree of osseointegration in the implants [55].

**Molecular Targets in the Treatment of Osteolysis**

At present osteoporosis treatment is based on two drug groups, antiresorptive and anabolic agents (Table 1).

The first to be introduced were antiresorptive agents that inhibit bone resorption and generate increased bone mineral density (BMD). Healing with bisphosphonates (BPs), which accelerate the apoptosis of osteoclasts and have shown their efficacy in reducing vertebral and non -vertebral fractures, is the gold standard therapy. Paget’s disease of bone, osteolytic bone metastases, and hypercalcemia are also treated with BPs. The chronic use of BPs may be outcome in both osseous and non -osseous adverse effects, and this has led to the search for alternatives [56]. Bisphosphonates inhibit farnesyl pyrophosphate synthase, an important enzyme required for synthesis of isoprenyl and geranylgeranyl, and inhibit prenylation and geranylgeranylation of small G-proteins such as Rac and Rho. This leads to defective actin ring formation at the sealed zone, a subcellular structure essential for bone resorption, and a decrease in bone resorption [57]. The bisphosphonate alendronate reduces the risk of hip, vertebral, and wrist fractures by 35%-39%. Zoledronate reduces the risk of hip fractures by 38% and of vertebral fractures by 62% [58]. Gold nanoparticles (GNPs) have been reported to influence the restoration of bone tissue in recent years. GNPs-ALD (Gold nanoparticles and alendronate) has the highest inhibitory effects towards osteoclast differentiation of bone marrow-derived macrophage [59]. Odanacatib, is a cathepsin K inhibitor, offers theoretical advantages over bisphosphonates. Since it does not reduce the number of osteoclasts and does not alter their function due the mechanism of action which different from that of other anti resorptive agents [60]. Receptor activator of NF-κ B ligand (RANKL)-induced formation of multinucleated osteoclasts is inhibited by Phloretin. It also diminished bone resorption area produced during the osteoclast differentiation process. The expression and secretion of cathepsin K elevated by RANKL was reported to diminish by Sub micro molar quantity of phloretin, being synchronized with inhibition of TRAP6 induction and NF-κ B activation. Phloretin also suppressed RANKL-induced activation of nuclear factor of activated T cells c1 (NFATc1) and microphthalmia-associated transcription factor [61]. Zinc inhibits osteoclast differentiation by suppression of Ca2+-Calcineurin-NFATc1 signaling pathway. Zinc is a significant inhibitory modulator throughout osteoclast differentiation that acts on the Ca2+-Calcineurin-NFATc1 signaling pathway. Silibinin is a component Silymarin-rich milk thistle extracts (MTE) which is reported to have enhanced alkaline phosphate activity of osteoblasts but reduced tartrate-resistant acid phosphatase (TRAP) activity of osteoclasts. Silibinin inhibited femoral bone loss induced by ovariectomy and suppressed femoral TRAP activity and cathepsin K induction accountable for bone resorption [62,63]. Fisetin, a flavonol found naturally in many fruits and vegetables, suppressed osteoclastogenesis by disturbing receptor activator of nuclear factor (NF)-κ B ligand (RANKL)-mediated signalling pathway and demoting osteoclastogenetic protein orientation. When fisetin was added to RANKL-exposed macrophages the formation of tartrate-resistance acid phosphatase-positive multinucleated osteoclasts was suppressed [64,65]. Carfilzomib inhibits PTH-induced RANKL expression and its oblique effect on osteoclastogenesis by blocking NF-κB activity in osteoclasts [66]. Salicortin inhibited RANKL-induced -c-Jun N-terminal kinase and NF-κ B activation, simultaneous with retarded IkBa phosphorylation and inhibition of p65 nuclear translocation, leading

<table>
<thead>
<tr>
<th>S. No</th>
<th>Anti resorptive agents</th>
<th>Molecular targets</th>
<th>Studies supporting the targeting compounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>PLA</td>
<td>NF-κB, MAPK</td>
<td>[68]</td>
</tr>
<tr>
<td>2</td>
<td>Melatonin</td>
<td>NF-κB, NFATc1</td>
<td>[69]</td>
</tr>
<tr>
<td>3</td>
<td>GNPs-ALD (Gold nanoparticles and alendronate)</td>
<td>Farnesyl pyrophosphate synthase</td>
<td>[61]</td>
</tr>
<tr>
<td>4</td>
<td>Carfilzomib</td>
<td>NF-κB</td>
<td>[66]</td>
</tr>
<tr>
<td>5</td>
<td>Salicortin</td>
<td>c-Jun N-terminal kinase, NF-κB, NFATc1</td>
<td>[67]</td>
</tr>
<tr>
<td>6</td>
<td>Fisetin</td>
<td>TRAP</td>
<td>[65]</td>
</tr>
<tr>
<td>7</td>
<td>Silibinin</td>
<td>TRAP and Cathepsin K</td>
<td>[64]</td>
</tr>
<tr>
<td>8</td>
<td>Zinc</td>
<td>Ca2+-Calcineurin</td>
<td>[72]</td>
</tr>
<tr>
<td>9</td>
<td>Phloretin</td>
<td>RANKL, Cathepsin K, TRAP6, NF-κB, NFATc1</td>
<td>[63]</td>
</tr>
<tr>
<td>10</td>
<td>Odanacatib</td>
<td>Cathepsin K</td>
<td>[62]</td>
</tr>
</tbody>
</table>

Table 1: Molecular targets to enhance bone health.
to impaired transcription of nuclear factor of activated T cells c1 (NFATc1) and expression of osteoclast-specific genes [67]. Palmitoleic acid (PLA) inhibits RANKL-induced formation of osteoclasts and interfered with the expression of osteoclast-specific genes in vitro. PLA inhibited the activation of the NF k B and MAPK pathways, offering a possible mechanism of action for its anti-osteoclastogenic effects. PLA further stimulated apoptosis in mature osteoclasts [68]. Melatonin directly suppressed osteoclasts differentiation through down regulation of NF k B pathway and following NFATc1 transcription factor induction. Notably, the anti-osteoclastogenic effect of melatonin was supposed to be independent of plasma membrane melanin receptors MT1/MT2. Since melatonin also has been known to increase osteoblast genesis and bone maturation, it might be beneficial for the use of melatonin in bone-resorption associated diseases [69,70].

Discussion and Conclusion

Hyperglycaemia in diabetic individuals, inhibit osteoblastic activity due to collagen growth, induces apoptosis in lining cells of bone and increases osteoclastic activity due to continuous inflammatory response. Bisphosphonates are commonly used to decrease bone resorption by inhibiting the activity of osteoclasts. This inhibition is due to many effects such as cytoskeletal disturbance, changing intracellular protein traffic, blocking intracellular signal transduction pathways, and induction of osteoclast apoptosis. By doing this, bisphosphonates suppress bone-resorption. Amongst bisphosphonates, 4-amino-l-hydroxybutylidene-1, l-bisphosphonate (alendronate, ALD), has been widely used to reduce bone fracture and to cause a continued increase in bone mineral density in postmenopausal osteoporotic subjects. Problems such as suppression of bone formation and jaw necrosis may occur due to excessive inhibition of bone resorption. This is due to difficulty with repairing small bone damage as the bone conversion is inhibited. This is especially prevalent with alveolar bone, which has a ratio of bone conversion 3-10 times higher than other bone tissue in the body. The oral mucosa, which is weaker and thinner than mucosa of other regions, can be negatively affected by the drugs. To avoid these effects, it is necessary to have a drug-delivery system using a carrier to target specific sites. Since no side effects have been reported the efficacy of products like PLA, melatonin, fisetin, silybin, phloretin, salicortin, cafiliomib and odanacatib with zinc supplementation seem to have a promising role on bone restoration in diabetic osteolyis.

References


